These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 30892086)
1. A Bicistronic Adenoviral Vector Carrying Cytosine Deaminase and Granulocyte-Macrophage Colony-Stimulating Factor Increases the Therapeutic Efficacy of Cancer Gene Therapy. Akbulut H; Coleri A; Sahin G; Tang Y; Icli F Hum Gene Ther; 2019 Aug; 30(8):999-1007. PubMed ID: 30892086 [TBL] [Abstract][Full Text] [Related]
2. Cytotoxic effect of replication-competent adenoviral vectors carrying L-plastin promoter regulated E1A and cytosine deaminase genes in cancers of the breast, ovary and colon. Akbulut H; Zhang L; Tang Y; Deisseroth A Cancer Gene Ther; 2003 May; 10(5):388-95. PubMed ID: 12719708 [TBL] [Abstract][Full Text] [Related]
3. Tumor-specific oncolytic adenoviruses expressing granulocyte macrophage colony-stimulating factor or anti-CTLA4 antibody for the treatment of cancers. Du T; Shi G; Li YM; Zhang JF; Tian HW; Wei YQ; Deng H; Yu DC Cancer Gene Ther; 2014 Aug; 21(8):340-8. PubMed ID: 25034886 [TBL] [Abstract][Full Text] [Related]
4. An Oncolytic Adenovirus Encoding Decorin and Granulocyte Macrophage Colony Stimulating Factor Inhibits Tumor Growth in a Colorectal Tumor Model by Targeting Pro-Tumorigenic Signals and via Immune Activation. Liu Z; Yang Y; Zhang X; Wang H; Xu W; Wang H; Xiao F; Bai Z; Yao H; Ma X; Jin L; Wu C; Seth P; Zhang Z; Wang L Hum Gene Ther; 2017 Aug; 28(8):667-680. PubMed ID: 28530155 [TBL] [Abstract][Full Text] [Related]
5. A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes. Hu ZB; Wu CT; Wang H; Zhang QW; Wang L; Wang RL; Lu ZZ; Wang LS Cancer Gene Ther; 2008 Mar; 15(3):173-82. PubMed ID: 18157145 [TBL] [Abstract][Full Text] [Related]
6. The use of the L-plastin promoter for adenoviral-mediated, tumor-specific gene expression in ovarian and bladder cancer cell lines. Peng XY; Won JH; Rutherford T; Fujii T; Zelterman D; Pizzorno G; Sapi E; Leavitt J; Kacinski B; Crystal R; Schwartz P; Deisseroth A Cancer Res; 2001 Jun; 61(11):4405-13. PubMed ID: 11389068 [TBL] [Abstract][Full Text] [Related]
7. Cytosine deaminase adenoviral vector and 5-fluorocytosine selectively reduce breast cancer cells 1 million-fold when they contaminate hematopoietic cells: a potential purging method for autologous transplantation. Garcia-Sanchez F; Pizzorno G; Fu SQ; Nanakorn T; Krause DS; Liang J; Adams E; Leffert JJ; Yin LH; Cooperberg MR; Hanania E; Wang WL; Won JH; Peng XY; Cote R; Brown R; Burtness B; Giles R; Crystal R; Deisseroth AB Blood; 1998 Jul; 92(2):672-82. PubMed ID: 9657770 [TBL] [Abstract][Full Text] [Related]
11. Concurrent delivery of GM-CSF and endostatin genes by a single adenoviral vector provides a synergistic effect on the treatment of orthotopic liver tumors. Tai KF; Chen PJ; Chen DS; Hwang LH J Gene Med; 2003 May; 5(5):386-98. PubMed ID: 12731087 [TBL] [Abstract][Full Text] [Related]
12. Engineering conditionally replication-competent adenoviral vectors carrying the cytosine deaminase gene increases the infectivity and therapeutic effect for breast cancer gene therapy. Liu Y; Ye T; Maynard J; Akbulut H; Deisseroth A Cancer Gene Ther; 2006 Apr; 13(4):346-56. PubMed ID: 16179927 [TBL] [Abstract][Full Text] [Related]
13. Strengthening of antitumor immune memory and prevention of thymic atrophy mediated by adenovirus expressing IL-12 and GM-CSF. Choi KJ; Zhang SN; Choi IK; Kim JS; Yun CO Gene Ther; 2012 Jul; 19(7):711-23. PubMed ID: 21993173 [TBL] [Abstract][Full Text] [Related]
14. A novel oncolytic adenovirus expressing Escherichia coli cytosine deaminase exhibits potent antitumor effect on human solid tumors. Zhang J; Wei F; Wang H; Li H; Qiu W; Ren P; Chen X; Huang Q Cancer Biother Radiopharm; 2010 Aug; 25(4):487-95. PubMed ID: 20735209 [TBL] [Abstract][Full Text] [Related]
15. Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect. Choi KJ; Kim JH; Lee YS; Kim J; Suh BS; Kim H; Cho S; Sohn JH; Kim GE; Yun CO Gene Ther; 2006 Jul; 13(13):1010-20. PubMed ID: 16525479 [TBL] [Abstract][Full Text] [Related]
16. Potentiation of oncolytic adenoviral vector efficacy with gutless vectors encoding GMCSF or TRAIL. Burroughs KD; Kayda DB; Sakhuja K; Hudson Y; Jakubczak J; Bristol JA; Ennist D; Hallenbeck P; Kaleko M; Connelly S Cancer Gene Ther; 2004 Feb; 11(2):92-102. PubMed ID: 14730331 [TBL] [Abstract][Full Text] [Related]
17. Adenovirus-mediated interleukin-12 gene transfer combined with cytosine deaminase followed by 5-fluorocytosine treatment exerts potent antitumor activity in Renca tumor-bearing mice. Hwang KS; Cho WK; Yoo J; Yun HJ; Kim S; Im DS BMC Cancer; 2005 May; 5():51. PubMed ID: 15910693 [TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo activities of an oncolytic adenoviral vector designed to express GM-CSF. Bristol JA; Zhu M; Ji H; Mina M; Xie Y; Clarke L; Forry-Schaudies S; Ennist DL Mol Ther; 2003 Jun; 7(6):755-64. PubMed ID: 12788649 [TBL] [Abstract][Full Text] [Related]
19. Enhanced antitumoral effect of adenovirus-mediated cytosine deaminase gene therapy by induction of antigen-presenting cells through stem cell factor/granulocyte-macrophage colony-stimulating factor gene transfer. Cao X; Huang X; Ju DW; Zhang W; Hamada H; Wang J Cancer Gene Ther; 2000 Feb; 7(2):177-86. PubMed ID: 10770625 [TBL] [Abstract][Full Text] [Related]
20. Oncolytic adenoviral vector carrying the cytosine deaminase gene for melanoma gene therapy. Liu Y; Deisseroth A Cancer Gene Ther; 2006 Sep; 13(9):845-55. PubMed ID: 16710344 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]